Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A11QVV0
Tue, 15.02.2022
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma
Ladenburg, Germany, 15 February 2022 - Heidelberg Pharma AG (FSE: HPHA) today announced that the first patient has been dosed with HDP-101 in a Phase I/IIa study at the Winship Cancer Institute of Emory University, A [ … ]
Thu, 28.10.2021
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Participates at Various Conferences
Ladenburg, Germany, 28 October 2021 - Heidelberg Pharma AG (FSE: HPHA) will present the company and its proprietary ATAC technology at several upcoming scientific and investor conferences. Heidelberg Pharma uses Amanitin as an innovative toxin to develop new cancer therapies tha [ … ]
Thu, 07.10.2021
Heidelberg Pharma AG
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2021
- Paul-Ehrlich-Institut follows the FDA in giving clearance to begin a Phase I/IIa trial of HDP-101; first trial centers initiated in the USA
- Gross issue proceeds of over EUR 20 million generated from private placement in June
- Significant advances made in partn [ … ]
Fri, 01.10.2021
Heidelberg Pharma AG
Ad hoc announcement - Inside information pursuant to Article 17 MAR
Heidelberg Pharma AG Announces Adjustment of Guidance
Ladenburg, Germany, 1 October 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that it has adjusted its guidance for the current fiscal year published in March 2021. This is due to lower development expenses because cli [ … ]
Thu, 09.09.2021
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences
Ladenburg, Germany, 9 September 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that they will present the company and its proprietary ATAC technology at several upcoming scientific a [ … ]
Tue, 07.09.2021
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma provides update on Phase I/IIa clinical trial with ATAC candidate HDP-101 in the US
- Compatibility tests for closed infusion system with HDP-101 successfully completed- Shipping of study medication to the US in preparation- Contract signed with first study center, MD Anderson Cancer Center; initiation of the ce [ … ]
Mon, 19.07.2021
Heidelberg Pharma AG
PRESS RELEASE
Paul Ehrlich Institute Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
- Initiation of the first German study center planned within the next few months
Ladenburg, Germany, 19 July 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that the German authority Paul Ehrlich Institute, Lang [ … ]
Thu, 08.07.2021
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Reports on First Half-Year 2021
- HDP-101: Application to initiate clinical trial green-lighted by the FDA in February 2021; Clinical trial centers prepare to receive their first patient; Clinical Trial Application submitted to the Paul Ehrlich Institute in Germany
- New preclinical data on the immunomodulatory po [ … ]
Thu, 17.06.2021
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces Participation at Various Conferences
Ladenburg, Germany, 17 June 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that they will present its proprietary ATAC technology at two upcoming scientific events. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amaniti [ … ]
Tue, 15.06.2021
Heidelberg Pharma AG
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN.
Ad hoc announcement - Inside information pursuant to Article 17 MAR
Heidelberg Pharma AG Raises EUR 20 Million From Private Placement
Ladenburg, Germany, 15 June 2021 - Heidelberg Pharma AG (FSE: HPHA) announced that it [ … ]